A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants - Trial NCT06368986
Access comprehensive clinical trial information for NCT06368986 through Pure Global AI's free database. This Phase 1 trial is sponsored by ViiV Healthcare and is currently Not yet recruiting. The study focuses on HIV Infections. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
ViiV Healthcare
Timeline & Enrollment
Phase 1
Apr 16, 2024
Jun 12, 2024
Primary Outcome
Area under the plasma concentration - time curve from time zero (pre-dose) to infinity time (AUC[0-inf]) of VH4011499,Area under the plasma drug concentration - time curve from zero (pre-dose) to the end of the dosing interval at steady state (AUC[0-tlast) of VH4011499,Maximum observed plasma drug concentration (Cmax) of VH4011499,Time to maximum observed plasma concentration (Tmax) of VH4011499
Summary
The purpose of this study is to evaluate effect of food (in fasted and fed conditions) on the
 bioavailability of CAI VH4011499.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06368986
Non-Device Trial